Flamel Technologies SA (NASDAQ:FLML) shares rose 4.1% on Wednesday . The company traded as high as $13.00 and last traded at $12.99, with a volume of 97,921 shares changing hands. The stock had previously closed at $12.48.

FLML has been the topic of a number of research analyst reports. Leerink Swann reiterated a “buy” rating and issued a $16.00 target price on shares of Flamel Technologies SA in a report on Tuesday, May 10th. Zacks Investment Research upgraded Flamel Technologies SA from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Flamel Technologies SA presently has a consensus rating of “Buy” and an average target price of $18.63.

The stock has a market cap of $517.99 million and a PE ratio of 23.79. The firm’s 50-day moving average price is $10.80 and its 200 day moving average price is $10.47.

Flamel Technologies SA (NASDAQ:FLML) last posted its quarterly earnings results on Monday, May 9th. The company reported $0.04 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by $0.10. The company had revenue of $36.20 million for the quarter, compared to the consensus estimate of $34 million. Flamel Technologies SA’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, equities analysts forecast that Flamel Technologies SA will post ($0.03) EPS for the current fiscal year.

In related news, CEO Michael S. Anderson purchased 5,000 shares of Flamel Technologies SA stock in a transaction that occurred on Thursday, May 12th. The stock was bought at an average price of $8.84 per share, for a total transaction of $44,200.00. Following the completion of the transaction, the chief executive officer now owns 134,250 shares in the company, valued at $1,186,770. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Craig R. Stapleton purchased 27,228 shares of Flamel Technologies SA stock in a transaction that occurred on Monday, May 16th. The shares were bought at an average price of $9.21 per share, with a total value of $250,769.88. Following the transaction, the director now owns 507,263 shares of the company’s stock, valued at approximately $4,671,892.23. The disclosure for this purchase can be found here.

A number of institutional investors recently bought and sold shares of the stock. Turner Investments L.P. raised its position in Flamel Technologies SA by 77.3% in the fourth quarter. Turner Investments L.P. now owns 239,308 shares of the company’s stock valued at $2,922,000 after buying an additional 104,340 shares during the last quarter. Morgan Stanley raised its position in shares of Flamel Technologies SA by 131.4% in the fourth quarter. Morgan Stanley now owns 719,463 shares of the company’s stock worth $8,785,000 after buying an additional 408,531 shares in the last quarter. Tekla Capital Management LLC acquired a new position in shares of Flamel Technologies SA during the fourth quarter worth $5,791,000. Sei Investments Co. acquired a new position in shares of Flamel Technologies SA during the fourth quarter worth $2,129,000. Finally, Russell Frank Co raised its position in shares of Flamel Technologies SA by 15.5% in the fourth quarter. Russell Frank Co now owns 422,247 shares of the company’s stock worth $6,118,000 after buying an additional 56,752 shares in the last quarter.

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.